Mirzaten (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten, is a tetracyclic antidepressant presented as an oral formulation for oral use. It treats major depressive disorder in adults and is prescribed when improvement of mood, sleep and appetite is needed.

GNH USA supplies Mirzaten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a tetracyclic antidepressant that acts on multiple neurotransmitter pathways to alleviate depressive conditions. - Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients. - Depressive episodes with insomnia: promotes sleep continuity and quality. - Depression with loss of appetite or weight loss: may increase appetite and lead to modest weight gain.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatic dysfunction or jaundice - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior, especially early in treatment - Seizures - Unexplained fever or rash

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Assess depression severity: ensure accurate diagnosis and consider suicide risk. - Monitor for suicidal ideation: especially during the first weeks of treatment. - Use caution in hepatic impairment: dose adjustments may be required. - Use caution in elderly patients: increased sensitivity to sedation and falls. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce efficacy. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): monitor for serotonin syndrome. - Anticholinergic drugs: may exacerbate dry mouth and constipation.